This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
PJ2 Overzicht aandelen
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Liminal BioSciences Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €3.80 |
| 52 Week Hoogtepunt | €5.32 |
| 52 Week Laag | €0.065 |
| Bèta | 30.72 |
| 11 maand verandering | 0% |
| 3 maanden verandering | 0% |
| 1 Jaar Verandering | -0.73% |
| 33 jaar verandering | -94.79% |
| 5 jaar verandering | -99.92% |
| Verandering sinds IPO | -99.81% |
Recent nieuws en updates
Recent updates
Rendement voor aandeelhouders
| PJ2 | DE Biotechs | DE Markt | |
|---|---|---|---|
| 7D | 0% | 0.7% | 1.1% |
| 1Y | -0.7% | -8.5% | 18.9% |
Rendement versus industrie: PJ2 exceeded the German Biotechs industry which returned -7.6% over the past year.
Rendement versus markt: PJ2 exceeded the German Market which returned -4.5% over the past year.
Prijsvolatiliteit
| PJ2 volatility | |
|---|---|
| PJ2 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stabiele aandelenkoers: PJ2 has not had significant price volatility in the past 3 months.
Volatiliteit in de loop van de tijd: Insufficient data to determine PJ2's volatility change over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1994 | n/a | Bruce Pritchard | www.liminalbiosciences.com |
Liminal BioSciences Inc. Samenvatting
| PJ2 fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €11.80m |
| Inkomsten(TTM) | -€19.54m |
| Inkomsten(TTM) | €269.81k |
43.7x
P/S-verhouding-0.6x
Koers/WinstverhoudingIs PJ2 overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| PJ2 resultatenrekening (TTM) | |
|---|---|
| Inkomsten | CA$401.00k |
| Kosten van inkomsten | CA$15.30m |
| Brutowinst | -CA$14.90m |
| Overige uitgaven | CA$14.14m |
| Inkomsten | -CA$29.04m |
Laatst gerapporteerde inkomsten
Dec 31, 2022
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -9.35 |
| Brutomarge | -3,714.96% |
| Nettowinstmarge | -7,241.40% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde PJ2 op de lange termijn?
Bekijk historische prestaties en vergelijking